| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
Purity: ≥98%
| Targets |
The molecular target of Hetrombopag olamine is the thrombopoietin receptor (TPO-R or MPL). It acts as an agonist, binding to the transmembrane domain of the receptor and activating TPO-R-dependent signaling pathways, including STAT and MAPK. This stimulates megakaryocyte proliferation and differentiation, leading to increased platelet production. Its mechanism mimics the biological effects of thrombopoietin.
|
|---|---|
| ln Vitro |
In vitro, Hetrombopag specifically stimulates proliferation and/or differentiation of human TPO-R-expressing cells, including 32D-MPL and human hematopoietic stem cells. It up-regulates G1-phase-related proteins, including p-RB, Cyclin D1, and CDK4/6, and modulates BCL-XL/BAK expression in 32D-MPL cells. Its potency is assessed by measuring cell proliferation and STAT activation.
|
| ln Vivo |
In vivo, Hetrombopag increases platelet counts in animal models of thrombocytopenia. Oral administration stimulates megakaryopoiesis and thrombopoiesis. It is used clinically for the treatment of chronic immune thrombocytopenia (ITP) and thrombocytopenia associated with hepatitis C. Its efficacy is dose-dependent and sustained with chronic dosing.
|
| Enzyme Assay |
Non-cellular binding assays for Hetrombopag olamine measure its binding to the TPO-R using surface plasmon resonance (SPR) or fluorescence polarization. The recombinant TPO-R extracellular domain is immobilized, and the compound is flowed over the surface to measure binding affinity. Alternatively, a fluorescently labeled TPO-R ligand is used in competition assays.
|
| Cell Assay |
In vitro cell-based experiments use TPO-R-expressing cell lines (e.g., 32D-MPL, UT-7/TPO). Cells are treated with Hetrombopag, and proliferation is measured by MTT or [3H]thymidine incorporation. STAT activation is assessed by Western blot. Megakaryocyte differentiation is evaluated by flow cytometry (CD41/CD61 expression).
|
| Animal Protocol |
In vivo animal experiments use mouse models of thrombocytopenia (e.g., carboplatin-induced or radiation-induced). Hetrombopag olamine is administered orally. Platelet counts are monitored. Bone marrow megakaryocytes are assessed by histology. Pharmacokinetic studies determine plasma drug concentrations and half-life.
|
| References |
[1]Drugs. 2021 Sep;81(13):1581-1585. doi: 10.1007/s40265-021-01575-1. [2] Safety,\nPharmacokinetics and Pharmacodynamics of Hetrombopag Olamine, a Novel\nTPO-R Agonist, in Healthy Subjects. Basic Clin Pharmacol Toxicol. 2017\nMay 24. doi: 10.1111/bcpt.12815. |
| Molecular Formula |
C29H36N6O7
|
|---|---|
| Molecular Weight |
580.64
|
| CAS # |
1257792-42-9
|
| Related CAS # |
[ ''''Related CAS 1257792-42-9 (olamine) 1257792-41-8 (free acid) 1257792-41-8 (ethanolamine)
|
| PubChem CID |
135565609
|
| Appearance |
Typically exists as solid at room temperature
|
| Hydrogen Bond Donor Count |
7
|
| Hydrogen Bond Acceptor Count |
12
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
42
|
| Complexity |
870
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C1N(N=C(/C1=N/NC2=C(C(C3=CC=C(C(O)=O)O3)=CC=C2)O)C)C4=CC=C(CCCC5)C5=C4.NCCO.NCCO
|
| InChi Key |
WPNAPESWZGRRPA-JGUILPGDSA-N
|
| InChi Code |
InChI=1S/C25H22N4O5.C2H7NO/c1-14-22(24(31)29(28-14)17-10-9-15-5-2-3-6-16(15)13-17)27-26-19-8-4-7-18(23(19)30)20-11-12-21(34-20)25(32)333-1-2-4/h4,7-13,28,30H,2-3,5-6H2,1H3,(H,32,33)4H,1-3H2/b27-26+
|
| Chemical Name |
2-Aminoethanol
5-{2-hydroxy-3-[5-methyl-3-oxo-2-(5,6,7,8-tetrahydro-naphthalen-2-yl)-2,3-dihydro-1H-pyrazol-4-ylazo]-phenyl}-furan-2-carboxylic
acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.7222 mL | 8.6112 mL | 17.2224 mL | |
| 5 mM | 0.3444 mL | 1.7222 mL | 3.4445 mL | |
| 10 mM | 0.1722 mL | 0.8611 mL | 1.7222 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.